Clinical Trial Update: A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous APD418 for hemodynamic effects, safety, tolerability, and pharmacokinetics in adults with heart failure with reduced ejecti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• APD418 (APD418)

Snippet

Sponsor: Pfizer | Conditions: Acute Heart Failure With Reduced Ejection Fraction | Phase 2 | Status: TERMINATED | Results posted: 2023-11-09